The US $600 million acquisition will see Juniper Biologics offer the world's first cell-mediated gene therapy to an estimated 300 million patients in Asia Pacific, Middle East and Africa
A novel second-generation approach to achieve a safe, durable, and stable transgene expression to overcome the challenges of factor VIII replacement therapies
Agreement builds on previous Novartis success using emerging technologies to develop first-in-class gene therapies for neurological disorders
Collaboration aims to evolve precision medicine with cell-specific delivery of gene therapy
It has exercised intellectual property options from IP Group regarding research results generated by the UK Cystic Fibrosis Gene Therapy Consortium, and from Oxford Biomedica regarding their lentiviral vector technology
New Gibco AAV-MAX Helper Free AAV Production System helps reduce production costs and streamline the transition from research to clinical environments
A dedicated Life Sciences Innovation Fund, scalable up to Rs. 1,000 crore, will catalyze early- and growth-stage innovation, support deep-tech ventures – particularly biotherapeutics
The RMAT designation accelerates the development of regenerative medicine therapies for serious or life-threatening diseases
The collaboration aims to accelerate the delivery of challenging DNA motifs with speed, precision, and reliability
India in the Changing Landscape of Life-Sciences Research & Development
Subscribe To Our Newsletter & Stay Updated
